A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
22 11 2021
Historique:
received: 22 06 2021
accepted: 28 09 2021
entrez: 23 11 2021
pubmed: 24 11 2021
medline: 15 12 2021
Statut: epublish

Résumé

Lipid nanoparticle (LNP)-formulated mRNA vaccines were rapidly developed and deployed in response to the SARS-CoV-2 pandemic. Due to the labile nature of mRNA, identifying impurities that could affect product stability and efficacy is crucial to the long-term use of nucleic-acid based medicines. Herein, reversed-phase ion pair high performance liquid chromatography (RP-IP HPLC) was used to identify a class of impurity formed through lipid:mRNA reactions; such reactions are typically undetectable by traditional mRNA purity analytical techniques. The identified modifications render the mRNA untranslatable, leading to loss of protein expression. Specifically, electrophilic impurities derived from the ionizable cationic lipid component are shown to be responsible. Mechanisms implicated in the formation of reactive species include oxidation and subsequent hydrolysis of the tertiary amine. It thus remains critical to ensure robust analytical methods and stringent manufacturing control to ensure mRNA stability and high activity in LNP delivery systems.

Identifiants

pubmed: 34811367
doi: 10.1038/s41467-021-26926-0
pii: 10.1038/s41467-021-26926-0
pmc: PMC8608879
doi:

Substances chimiques

Aldehydes 0
Ions 0
Lipid Nanoparticles 0
Lipids 0
Liposomes 0
Nucleosides 0
RNA, Messenger 0
mRNA Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6777

Informations de copyright

© 2021. The Author(s).

Références

Nucleic Acids Res. 2001 Jan 15;29(2):E7
pubmed: 11139637
Nanomaterials (Basel). 2020 Feb 20;10(2):
pubmed: 32093140
Nat Biotechnol. 2013 Jul;31(7):638-46
pubmed: 23792630
J Pharm Sci. 2021 Mar;110(3):997-1001
pubmed: 33321139
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2018 Jan 11;553(7687):171-177
pubmed: 29323295
J Pharm Sci. 2000 Apr;89(4):443-56
pubmed: 10737906
Sci Rep. 2019 Jan 31;9(1):1019
pubmed: 30705318
Mol Ther. 2019 Apr 10;27(4):710-728
pubmed: 30846391
Pharm Res. 2021 Mar;38(3):473-478
pubmed: 33660201
Sci Adv. 2020 Jun 24;6(26):eaaz6893
pubmed: 32637598
Cell. 2009 Feb 20;136(4):763-76
pubmed: 19239894
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Mol Pharm. 2021 Jan 4;18(1):377-385
pubmed: 33295773
Free Radic Biol Med. 1996;20(2):225-36
pubmed: 8746443
Bioorg Med Chem Lett. 2010 Aug 1;20(15):4499-502
pubmed: 20584607
Nano Today. 2021 Jun;38:101142
pubmed: 33815564
Adv Mater. 2016 Apr 20;28(15):2939-43
pubmed: 26889757
Mol Ther. 2018 Mar 7;26(3):801-813
pubmed: 29433939
Front Chem. 2020 Oct 23;8:589959
pubmed: 33195094
Mol Ther. 2018 Jun 6;26(6):1509-1519
pubmed: 29653760
Sci Adv. 2021 Feb 26;7(9):
pubmed: 33637537
Biomater Sci. 2021 Feb 21;9(4):1449-1463
pubmed: 33404020
Ther Deliv. 2016;7(5):319-34
pubmed: 27075952
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 1;879(19):1587-95
pubmed: 21514903
Mol Ther. 2017 Jul 5;25(7):1467-1475
pubmed: 28412170
J Control Release. 2005 Oct 3;107(2):276-87
pubmed: 16054724
Front Chem. 2019 Jul 09;7:491
pubmed: 31338364
Nat Mater. 2021 May;20(5):701-710
pubmed: 33542471

Auteurs

Meredith Packer (M)

Moderna, Inc., 200 Technology Square, Cambridge, MA, USA.

Dipendra Gyawali (D)

Moderna, Inc., 200 Technology Square, Cambridge, MA, USA.

Ravikiran Yerabolu (R)

Moderna, Inc., 200 Technology Square, Cambridge, MA, USA.

Joseph Schariter (J)

Moderna, Inc., 200 Technology Square, Cambridge, MA, USA.

Phil White (P)

Moderna, Inc., 200 Technology Square, Cambridge, MA, USA. phil.white@modernatx.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH